186 related articles for article (PubMed ID: 27009937)
1. The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study.
He EY; Hawkins NJ; Mak G; Roncolato F; Goldstein D; Liauw W; Clingan P; Chin M; Ward RL
Oncologist; 2016 May; 21(5):618-25. PubMed ID: 27009937
[TBL] [Abstract][Full Text] [Related]
2. Microsatellite instability in mismatch repair proficient colorectal cancer: clinical features and underlying molecular mechanisms.
Xu Y; Liu K; Li C; Li M; Zhou X; Sun M; Zhang L; Wang S; Liu F; Xu Y
EBioMedicine; 2024 May; 103():105142. PubMed ID: 38691939
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological features and prognoses in younger and older patients with mismatch repair defects colorectal cancer: a retrospective comparative cohort study.
Zhang J; Li S; Ma P; Zhang J; Cao Y; Liu C; Zhang X; Li Z; Li C; Zhao Y
J Gastrointest Oncol; 2024 Feb; 15(1):260-270. PubMed ID: 38482236
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGE.
Cartwright E; Slater S; Saffery C; Tran A; Turkes F; Smith G; Aresu M; Kohoutova D; Terlizzo M; Zhitkov O; Rana I; Johnston EW; Sanna I; Smyth E; Mansoor W; Fribbens C; Rao S; Chau I; Starling N; Cunningham D
ESMO Open; 2024 Apr; 9(4):102971. PubMed ID: 38518549
[TBL] [Abstract][Full Text] [Related]
5. The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data.
Aydin SG; Olmez OF; Selvi O; Geredeli C; Ozden F; Bilici A; Acikgoz O; Karci E; Kutlu Y; Hamdard J; Aydin A
J Gastrointest Cancer; 2024 Mar; 55(1):227-236. PubMed ID: 37347353
[TBL] [Abstract][Full Text] [Related]
6. Improved Risk-Stratification Scheme for Mismatch-Repair Proficient Stage II Colorectal Cancers Using the Digital Pathology Biomarker QuantCRC.
Wu C; Pai RK; Kosiorek H; Banerjee I; Pfeiffer A; Hagen CE; Hartley CP; Graham RP; Sonbol MB; Bekaii-Saab T; Xie H; Sinicrope FA; Patel B; Westerling-Bui T; Shivji S; Conner J; Swallow C; Savage P; Cyr DP; Kirsch R; Pai RK
Clin Cancer Res; 2024 May; 30(9):1811-1821. PubMed ID: 38421684
[TBL] [Abstract][Full Text] [Related]
7. A Panel-Based Mutational Signature of Mismatch Repair Deficiency is Associated With Durable Response to Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer.
Boiarsky D; Gulhan DC; Savignano H; Lakshminarayanan G; McClure HM; Silver R; Hirsch MS; Sholl LM; Choudhury AD; Ananda G; Park PJ; Tewari AK; Berchuck JE
Clin Genitourin Cancer; 2024 Apr; 22(2):558-568.e3. PubMed ID: 38342659
[TBL] [Abstract][Full Text] [Related]
8. Challenges in the management of stage II colon cancer.
Dotan E; Cohen SJ
Semin Oncol; 2011 Aug; 38(4):511-20. PubMed ID: 21810510
[TBL] [Abstract][Full Text] [Related]
9. Microsatellite Instability in Sporadic Colorectal Malignancy: A Pilot Study from Northern India.
Chauhan S; Kumar S; Singh P; Husain N; Masood S
Asian Pac J Cancer Prev; 2021 Jul; 22(7):2279-2288. PubMed ID: 34319053
[TBL] [Abstract][Full Text] [Related]
10. Mismatch repair status and surgical approach in apparent early-stage endometrial cancer.
Morton R; Webb PM; Na R; Obermair A; Farrell R
Int J Gynecol Cancer; 2024 Apr; 34(4):535-543. PubMed ID: 38431289
[TBL] [Abstract][Full Text] [Related]
11. Cholecystectomy and the risk of colorectal cancer by tumor mismatch repair deficiency status.
Shang J; Reece JC; Buchanan DD; Giles GG; Figueiredo JC; Casey G; Gallinger S; Thibodeau SN; Lindor NM; Newcomb PA; Potter JD; Baron JA; Hopper JL; Jenkins MA; Win AK
Int J Colorectal Dis; 2016 Aug; 31(8):1451-7. PubMed ID: 27286977
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies.
Domingo E; Kelly C; Hay J; Sansom O; Maka N; Oien K; Iveson T; Saunders M; Kerr R; Tomlinson I; Edwards J; Harkin A; Nowak M; Koelzer V; Easton A; Boukovinas I; Moustou E; Messaritakis I; Chondrozoumaki M; Karagianni M; Pagès F; Arnoux F; Lautard C; Lovera Y; Boquet I; Catteau A; Galon J; ; Souglakos I; Church DN
J Clin Oncol; 2024 Mar; ():JCO2301648. PubMed ID: 38484206
[TBL] [Abstract][Full Text] [Related]
13. Real-world prevalence of microsatellite instability testing and related status in women with advanced endometrial cancer in Europe.
Kelkar SS; Prabhu VS; Zhang J; Ogando YM; Roney K; Verma RP; Miles N; Marth C
Arch Gynecol Obstet; 2024 Apr; ():. PubMed ID: 38634898
[TBL] [Abstract][Full Text] [Related]
14. Microsatellite instability is highly prevalent in older patients with colorectal cancer.
Jakob D; Orth V; Gödde D; Zirngibl H; Ambe PC
Front Surg; 2024; 11():1288061. PubMed ID: 38601878
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant Chemotherapy for Older Patients With Stage III Colorectal Cancer: A Real-World Analysis of Treatment Recommendations, Treatment Administered and Impact on Cancer Recurrence.
Piercey O; Wong HL; Leung C; To YH; Heong V; Lee M; Tie J; Steel M; Yeung JM; McCormick J; Gibbs P; Wong R
Clin Colorectal Cancer; 2024 Mar; 23(1):95-103.e3. PubMed ID: 38242766
[TBL] [Abstract][Full Text] [Related]
16. Physicians' beliefs about the benefits and risks of adjuvant therapies for stage II and stage III colorectal cancer.
Wong AC; Stock S; Schrag D; Kahn KL; Salz T; Charlton ME; Rogers SO; Goodman KA; Keating NL
J Oncol Pract; 2014 Sep; 10(5):e360-7. PubMed ID: 24986112
[TBL] [Abstract][Full Text] [Related]
17. Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer.
Bogani G; Monk BJ; Powell MA; Westin SN; Slomovitz B; Moore KN; Eskander RN; Raspagliesi F; Barretina-Ginesta MP; Colombo N; Mirza MR
Ann Oncol; 2024 May; 35(5):414-428. PubMed ID: 38431043
[TBL] [Abstract][Full Text] [Related]
18. Value of Real-World Evidence for Treatment Selection: A Case Study in Colon Cancer.
Shen L; van Gestel A; Prinsen P; Vink G; van Erning FN; Geleijnse G; Kaptein M
JCO Clin Cancer Inform; 2024 May; 8():e2300186. PubMed ID: 38753347
[TBL] [Abstract][Full Text] [Related]
19. Making sense of adjuvant chemotherapy in colorectal cancer.
Chan GHJ; Chee CE
J Gastrointest Oncol; 2019 Dec; 10(6):1183-1192. PubMed ID: 31949938
[TBL] [Abstract][Full Text] [Related]
20. Do treatment patterns differ in those with early-onset colorectal cancer?
Waddell O; Teo Y; Thompson N; McCombie A; Glyn T; Frizelle F
Expert Rev Anticancer Ther; 2024 May; 24(5):313-323. PubMed ID: 38619285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
